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Abstract
Background: Predicting drug-protein interactions from heterogeneous biological data sources is a key step for in
silico drug discovery. The diﬃculty of this prediction task lies in the rarity of known drug-protein interactions
and myriad unknown interactions to be predicted. To meet this challenge, a manifold regularization
semi-supervised learning method is presented to tackle this issue by using labeled and unlabeled information
which often generates better results than using the labeled data alone. Furthermore, our semi-supervised
learning method integrates known drug-protein interaction network information as well as chemical structure and
genomic sequence data.
Results: Using the proposed method, we predicted certain drug-protein interactions on the enzyme, ion channel,
GPCRs, and nuclear receptor data sets. Some of them are conﬁrmed by the latest publicly available drug targets
databases such as KEGG.
Conclusions: We report encouraging results of using our method for drug-protein interaction network
reconstruction which may shed light on the molecular interaction inference and new uses of marketed drugs.
1Background
Developing a new drug is an expensive and time-consuming process that is subject to a variety of
regulations such as drug toxicity monitoring and therapeutic eﬃcacy. Meanwhile, there are thousands of
FDA-approved drugs in the market and drugs in later phases of clinical trials. Finding the potential
application in other therapeutic categories of those FDA-approved drugs by predicting their targets, known
as drug repositioning, is an eﬃcient and time-saving method in drug discovery [1]. Additionally, predicting
interactions between drugs and target proteins can help decipher the underlying biological mechanisms.
Therefore, there is a strong incentive to develop powerful statistical methods that are capable of detecting
these potential drug-protein interactions eﬀectively.
Various methods have been proposed to address the drug-target prediction problems in silico. One
common method is to predict the drugs interacting with a single given protein based on the chemical
structure similarity in a classic classiﬁcation framework. Keiser et al. [2,3] proposed a method to predict
targets of proteins based on the chemical similarity of their ligands. This kind of approach, however, does
not take advantage of the information in the protein domain. Another widely-used method is molecular
docking [4] which requires the non-trivial modeling of 3D structure of the target protein. Unfortunately the
3D structures of many proteins are not available [5], e.g., very few GPCRs have been crystallized.
Recently, some new approaches are proposed to perform drug-target prediction using both the chemical
(drug chemical structure) and genomic (protein structure) spaces information [3,6,7]. In [6] the two spaces
are encoded together by deﬁning a pair wise kernel which is then fed to the support vector machine (SVM)
for classiﬁcation. The drawback of this kernel framework is that there will be a huge number of samples to
be classiﬁed (i.e., number of drugs multiplies number of proteins) which poses signiﬁcant computational
complexity. Another problem is that the negative drug-protein pairs are selected randomly without
experimental conﬁrmation. Yamanishi et al. [7] developed a bipartite graph model where the chemical and
genomic spaces as well as the drug-protein interaction network are integrated into a pharmacological space.
In the bipartite model, the known interactions in the training data are labeled as +1 while all other
unknown drug-protein pairs in the training data are assumed as non-interactions with label 0. Then three
diﬀerent classiﬁers are available: new drug candidate versus known target protein, known drugs versus new
target protein and new drug candidate versus new target protein candidate. More recently, Bleakley and
Yamanishi [8] proposed a state-of-the-art bipartite local model (BLM) by transforming edge-prediction
problems into well-known binary classiﬁcation problems. Nevertheless, the ﬁrst ﬂaw of the bipartite model,
like the kernel SVM method [6], is that the unknown interactions of the drugs and proteins in the training
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whether one drug-protein pair interacts or not. Lastly, all the methods did not utilize a wealth of unlabeled
information to assist prediction.
In this paper, a semi-supervised learning method - Laplacian regularized least square (LapRLS) [9] is
employed to utilize both the small amount of available labeled data and the abundant unlabeled data
together in order to give the maximum generalization ability from the chemical and genomic spaces.
Further, the standard LapRLS is improved by incorporating a new kernel established from the known
drug-protein interaction network (NetLapRLS). In our framework, the known interactions are labeled as
+1 and all other unknown pairs are labeled as 0 to indicate they are going to be predicted. Two classiﬁers
are trained on the drug and protein domains respectively and then are combined together to give the ﬁnal
prediction. Compared with a naive weighted proﬁled method, the proposed drug-protein interaction
methods based on LapRLS and NetLapRLS obtain better results than using the labeled data alone. And
the proposed NetLapRLS which incorporates drug-protein network information provides superior
performance than standard LapRLS.
Results and Discussion
Cross validation results analysis
The weighted proﬁle method, standard LapRLS and NetLapRLS were evaluated on the four classes of
target proteins including enzymes, ion channels, GPCRs and nuclear receptors. We carried out a ten-fold
cross-validation by splitting the golden standard interaction dataset into 10 subsets. Each fold was then
taken in turn as a test set and the remaining nine folds are used as training set. For example, there are 54
drugs and 26 proteins in the nuclear receptor data set with 90 known interactions. In each cross-validation,
the 80 drug-protein pairs are used as the training data while the remaining 1,324 drug-protein pairs
including the 10 positive interactions are designated as the testing data set. Thus the training sample is
very small compared with the testing data set. This motivates us to employ the semi-supervised method
that can utilize the information from the unlabeled samples to predict drug-protein interaction. The
performance is evaluated using receiver operating curve (ROC) analysis [10]. For simplicity, we set
d = p = 0:3, 
d1 = 
p1 = 1, and 
d2 = 
p2 = 0:01 for NetLapRLS. These parameters can be better
selected by a further cross validation. If 
d2 and 
p2 are set to be 0, NetLapRLS becomes the standard
LapRLS method. Table 1 shows the AUC (area under the ROC curve), sensitivity and speciﬁcity. The
sensitivity and speciﬁcity are deﬁned as TP/(TP+FN) and TN/(TN+FP), respectively. The cutoﬀ for
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From Table 1 and Figure 1, we can see that LapRLS and NetLapRLS methods, which use unlabeled
information, provided better performance with respect to AUC score and sensitivity. Among the four data
sets, the two semi-supervised learning methods provided the highest sensitivity scores in enzyme data set
because there are most known interactions. The known interaction number is a key factor of our
semi-supervised methods since the testing data set is much larger than training data set in our
cross-validation setup. The proposed NetLapRLS which incorporates the drug-protein interaction network
information obtained better result than the standard LapRLS, especially with respective to the sensitivity
which is dramatically improved. On the four data sets, the sensitivity from NetLapRLS performed better
than LapRLS by 42%, 100%, 108% and 31% respectively and, demonstrated the importance of network
information. The improvement in sensitivity of NetLapRLS over LapRLS is most signiﬁcant in ion channel
data set because the inner-connection in the ion channel drug-protein interaction network is most complete
according to the proportion of unreachable paths between drugs and proteins [7]. Yildirim et al. [11]
concluded that there are an overabundance of ’follow-on’ drugs from the topological analyses of current
drug-protein network, that is, drugs that target already known proteins, i.e., me-too drugs. With the
drug-protein network being completed fastly by high-throughput experimental and computational
approaches, this network information is becoming critical in drug discovery.
Comparison with bipartite local model [8]
Recently, Bleakley and Yamanishi [8] extended Yamanishi’s bipartite method [12] to bipartite local model
which is considered as state-of-the-art. The predictions from the drug domain and protein domain using
SVM are combined together to form a ﬁnal prediction by a maximum operation. We also employed this
kind of integration by a mean operation. However, we used a semi-supervised learning method to handle
the classiﬁcation with small samples labeled which is diﬃcult for traditional supervised classiﬁers. For
instance, in the above cross-validation experiment of the nuclear receptor data set, the semi-supervised
classiﬁer is trained on 80 positive samples in order to make predictions on 1,324 unlabeled samples. In the
BLM, the ten-fold cross-validation is performed on the drug and protein domains separately. The known
interactions between the selected drugs and proteins are labeled as interaction while interactions between
the drugs and proteins for training are regarded as non-interaction. Though we consider the undetermined
relationship between drug-protein pair should not be labeled as non-interaction, we adopt the cross
validation method in the BLM for the sake of comparison in the same condition. The comparison is
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in Table 2. Sensitivity, speciﬁcity and PPV are calculated when the top one percentile in the prediction
score is chosen as a cutoﬀ because high-conﬁdence prediction results are more useful in practical
applications. We observed that BLM method outperformed our NetLapRLS in AUC and AUPR scores,
but the performances of our NetLapRLS are comparable with BLM in sensitivity, speciﬁcity and PPV.
Semi-supervised learning method is superior to the traditional supervised learning method when labeled
samples are small along with large unlabeled samples available. In this cross validation setup, the unknown
interactions are labeled as non-interaction in the training data set. So our NetLapRLS did not get good
results in AUC and AUPR scores compared with BLM because most of samples are labeled. However,
NetLapRLS still gave good prediction results in sensitivity, speciﬁcity and PPV. This indicated that
NetLapRLS can provide a list of drug-protein interaction candidates with high conﬁdence.
Enzyme
Table 3 shows the list of the top 5 predicted drug-protein pairs, with annotation given in the KEGG
database [13]. Searching the latest version of KEGG drug database and Drugbank [14], we found that the
ﬁfth highest scored drug-protein pair (D00097 and hsa5743) in Table 3 is annotated as an interaction.
Figure 2 shows the predicted top 50 scoring drug-protein interaction network on the enzyme data using the
all known interactions as the training data set.
Ion channel
Table 4 shows the list of the top ﬁve predicted drug-protein pairs on the ion channel data set, with
annotation given in the KEGG database [13]. In the latest version of KEGG drug database, the targets of
drug D00477 (rank 2 in table 4) include SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A and SCN9A.
The targets of drug D00552 are SCN10A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A and SCN9A.
Thus, our predicted target of D00552 is conﬁrmed (rank 3 in Table 4). The targets of drugs D00477 and
D00552 are very similar which can be explained by their common chemical structures in Figure 3. Based
on the chemical structure similarity, we predict that SCN10A is also a target of drug D00477 (rank 2 in
table 4), as the interaction between SCN10A and D00552 is known. Rank 5 in table 4 predicts GABAR2 is
one of the targets of drug D00546. This prediction is reasonable because in Drugbank D00546 is annotated
to interact with GABAR1 which is very similar with GABAR2 in sequence and function. Figure 4 shows
the predicted top 50 scoring drug-protein interaction network on the ion channel data set using the all
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GPCRs
Table 5 shows the list of the top ﬁve predicted drug-protein pairs on GPCRs data set, with annotation
given in KEGG database. Based on the most recent KEGG database, the predictions of rank 2 and 3 in
Table 5 are conﬁrmed. Additionally, six predicted new targets (hsa146, hsa147, hsa150, hsa151, hsa152 and
hsa155) of drug adrenaline (D00095) from the newly predicted interactions with 50 highest scores are also
annotated as an interaction in the latest KEGG drug database. Ranks 4 and 5 in Table 5 predict both
D02345 and D00283 target protein DRD3. In Drugbank, D02345 and D00283 are annotated to interact
with protein DRD1, DRD2, and DRD4. Because DRD3 is very similar with those proteins in function, our
method predicts DRD3 is also the target of drugs D02345 and D00283. This result demonstrated our
method employed the information from protein domain. Figure 5 shows the predicted top 50 scoring
drug-protein interaction network on the GPCRs data set using the all known interactions as the training
data set.
Nuclear receptor
Table 6 shows the list of the top 5 predicted drug-protein pairs on nuclear receptor data set, among which
four predictions are about drug D00348. In Drugbank, drug D00348 is annotated to interact with protein
(retinoic acid receptor, alpha). The two predicted targets with the highest scores (hsa5915 and hsa5916) of
drug D00348 are both from retinoic acid receptor class. Those proteins are probably as the targets of the
same protein due to their similarity in sequence and function. Figure 6 shows the predicted top 50 scoring
drug-protein interaction network on the nuclear receptor data set with the all known interactions as the
training data set.
Conclusions
In this work, we presented a semi-supervised learning method NetLapRLS for drug-protein interaction
prediction by integrating information from chemical space, genomic space and drug-protein interaction
network space. Our method has no use of the negative samples and predicts the interaction of each
drug-protein pair. The results we obtained when predicting human drug-target interaction networks
involving enzymes, ion channels, GPCRs, and nuclear receptors demonstrated the superior performance of
NetLapRLS. Furthermore, recently added drug-target interactions to the KEGG immediately allowed us to
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This enhances the strength of our proposed method for realistic drug-target prediction application.
The ideal way to use semi-supervised learning for predicting compound-protein interactions is to
incorporate information from diﬀerent biological spaces by a multi-task kernel and is fed to classical
semi-supervised learning. However, the implementation of such a large scale semi-supervised learning
method will be computationaly costly. Our future work, will incorporate more sophisticated and
biologically relevant information into the kernel similarity, such as side eﬀect [15], to improve the
prediction accuracy.
Methods
Semi-supervised learning (SSL) has been attracting much research attention in the machine learning
community [16]. SSL provides better prediction accuracy by using unlabeled information. Here we employ
a data-dependent manifold regularization framework which uses the geometry of the probability
distribution [9]. One of the implementations of this framework is the Laplacian regularized least squares
(LapRLS) which is simple and has comparable performance with Laplacian regularized support vector
machine.
Consider the drug dataset D = {d1;:::;dnd} and the target protein dataset P = {p1;:::;pnp} where nd and
np are the numbers of the drugs and proteins in the study respectively. An interaction pattern of drug di
and target protein pj is represented by a binary label matrix Y ∈ Bndnp. If drug di is known to interact
with target protein pj, Yij = 1 otherwise Yij = 0. Given the ’gold standard’ drug-target interactions, the
goal is to infer their unknown interactions. Two classiﬁers will be trained using LapRLS on the chemical
and genomic spaces separately, followed by a combination of the two classiﬁers. A supervised learning
method is suitable in this case. However the known interactions from public databases are still extremely
small compared to the whole drug-target interaction space. Another issue is that we only have the
information of the interactions, but do not know which drug target pair has no interaction, i.e., no negative
samples in the training process. Herein we ﬁrst test a simple supervised weighted proﬁle method. Then the
standard LapRLS and drug-protein interaction network incorporated NetLapRLS are extended to predict
the drug-protein interaction.
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The data used here is downloaded from ⟨http://web.kuicr.kyoto-u.ac.jp/supp/yoshi/drugtarget/⟩ [7]. Here
below we provide a brief description.
• Chemical data
The chemical structure similarity between compounds are calculated by SIMCOMP [17] using
chemical structures fetched from KEGG LIGAND database. SIMCOMP provides a global similarity
score by the ratio between the size of common substructures and the size of the union structures of
two compounds. Applying this operation to all compounds pairs, we constructed a similarity matrix
denoted Sd ∈ Rndnd which represents the chemical space information.
• Genomic data
A normalized Smith-Waterman score is calculated to indicate the similarity between two amino acid
sequences of target proteins which were obtained from the KEGG GENES database. All protein
pairs similarities are computed to construct a similarity matrix denoted Sp ∈ Rnpnp which
represents the genomic space.
• Drug-protein interaction data
At the time of the paper [7] was written, Yamanishi et al. [7] found 445, 210, 223, and 54 drugs
targeting 664 enzymes, 204 iron channels, 95 GPCRs, and 26 nuclear receptors, receptively, and the
known interactions are 2926, 1476, 635 and 90.
Combining weighted proles
The method of combining weighted proﬁles follows the idea that the label of the new sample is determined
by its similarity with the training samples. For a drug di, its interaction f(di;pj) with a protein pj in P is
predicted with the following formulation:
f(di;pj) =
1
Ndi
nd ∑
k=1
sd(di;dk)Ykj (1)
where sd(di;dk) is a chemical structure similarity score from Sd and Ndi is a normalization term deﬁned as
Ndi =
∑nd
k=1 sd(di;dk). Meanwhile, for a protein pj, its interaction f(pj;di) with a drug di can also be
calculated in the genomic space by:
f(pj;di) =
1
Npj
np ∑
k=1
sp(pj;pk)Yik (2)
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Npj =
∑np
k=1 sp(pj;pk). Note that Equations (1) and (2) are estimating the interaction of the same
drug-protein pair (di ∼ pj) from diﬀerent data sources. The two predictions should be combined to give
the ﬁnal prediction by
¯ f(di;pj) =
f(di;pj) + f(pj;di)
2
: (3)
The drug-protein pairs (di;pj) in ¯ f(di;pj) with high scores are predicted to interact each other. The
original weighted proﬁle method is used in [7]. However their predictions in the two spaces are not fused.
Figure 7 shows the method of combining weighted proﬁles provides better prediction than methods using
the single space on the four data sets.
LapRLS and NetLapRLS for drug-protein interaction prediction
In LapRLS and NetLapRLS, the data-dependent regularization terms are normalized Laplacian operation
on graphs. Herein two undirected graphs of drug domain and protein domain including both labeled and
unlabeled samples are represented by Gd = {Vd;Ed} and Gp = {Vp;Ep} ,where the set of nodes or vertices is
Vd = {di}, Vp = {pi} and the set of edges is Ed = {edmn}, Ep = {epmn} respectively. Each drug di or
protein pj is treated as the node on the graph and the weight of edge edmn(epmn) is wdmn(wpmn).
Typically, the weight measures the similarity between two nodes. In our case, the drug domain similarity
Wd = {wdmn} is obtained by combining the chemical similarity Sd and drug-target interaction network.
The protein domain similarity Wp = {wpmn} is derived by combining the genomic similarity Sp and
drug-protein interaction network spaces. The chemical similarity Sd and genomic similarity Sp have
already been introduced in Section Materials.
Next we need to extract the information from the drug-protein interaction network space. The underlying
assumption made here is that if two drugs share more target proteins, they are more similar. For example,
in Figure 8, the blue line means the known drug-protein interaction while the red line represents the
interaction to be predicted. So drug D2 shares 3 same proteins with drug D1 while drug D3 shares a
common protein with drug D1. Drug D1 interacts with Protein P4. Based on the assumption here, we can
infer that it is more probable that drug D2 interacts with protein P4 than drug D3 does. So another
similarity matrix for drug domain from drug-protein interaction network Kd ∈ Rndnd can be established
whose each entry is the number of proteins shared by drug di and dj. Similarly, we can also derive the
network similarity matrix Kp ∈ Rnpnp whose each entry is the number of drugs shared by protein pj and
pi. Though drug-protein interaction network was also used in [7], our method employs a diﬀerent way to
9extract information from the network. The shortest path concept is used in [7] while we utilize the number
of common nodes shared by two proteins(drugs) to indicate a new similarity measurement.
Now the drug domain similarity Wd can be derived from the chemical similarity and drug-protein network
similarity by linear combination Wd =

d1Sd+
d2Kd

d1+
d2 . Similarly, the protein domain similarity Wp can be
obtained by Wp =

p1Sp+
p2Kp

p1+
p2 . Compared with the standard LapRLS , our NetLapRLS incorporates
drug-protein network information into the prediction model. In the following paragraph, we just describe
the method NetLapRLS from which the standard LapRLS can be deduced by setting 
d2 = 
p2 = 0.
Given the similarity matrices of drug domain and protein domain, we ﬁrst perform Laplacian operation on
the two graphs which is required by our semi-supervised learning method. The node degree matrices Dd
and Dp are two diagonal matrices with their (k;k)-element deﬁned as Dd(k;k) =
∑nd
m=1 wdk;m and
Dp(k;k) =
∑np
m=1 wpk;m. The Laplacian operation of the two graphs is deﬁned as ∆d = Dd − Wd and
∆p = Dp − Wp respectively. The normalized graph Laplacians are
Ld = D
 1=2
d ∆dD
 1=2
d = Indnd − D
 1=2
d WdD
 1=2
d and Lp = D
 1=2
p ∆pD
 1=2
p = Inpnp − D
 1=2
p WpD
 1=2
p
respectively.
NetLapRLS deﬁnes a continuous classiﬁcation function F that is estimated on the graph to minimize a cost
function. The cost function typically enforces a trade-oﬀ between the smoothness of the function on the
graph of both labeled and unlabeled data and the accuracy of the function at ﬁtting the label information
for the labeled nodes. Herein we extend NetLapRLS to the matrix form. The two continuous classiﬁcation
functions are deﬁned by Fd ∈ Rndnp and Fp ∈ Rnpnd. Let’s ﬁrst address the prediction Fd on the drug
domain. The cost function of NetLapRLS is deﬁned as follows
F
d = min
Fd
J(Fd) = ∥Y − Fd∥2
F + dTrace(FT
d LdFd) (4)
where ∥·∥F is Frobenius norm and Trace is the trace of a matrix. Representer theorem [18] shows that the
solution is a linear combination
F
d = Wd
d
Substituting this form into equation (4), we arrive at a convex diﬀerentiable objective function with respect
to variable d ∈ Rndnp

d = arg min
d2Rndnp
{∥Y − Wdd∥2
F + dTrace(T
d WdLdWdd)} (5)
The derivative of the objective function vanishes at the minimizer:
−Wd(Y − Wdd) + dWdLdKdd = 0 (6)
10which leads to the following solution:

d = (Wd + dLdWd) 1Y (7)
Then we get the prediction from the drug domain in the following form:
F
d = Wd(Wd + dLdWd) 1Y (8)
Similarly, we can also derive the prediction in the protein domain by
F
p = Wp(Wp + pLpWp) 1YT (9)
In the end, the predictions from drug and protein domains are combined into
F =
F
d + (F
p)T
2
(10)
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Figures
Figure 1 - ROC curves of cross validation
ROC curves of the semi-supervised learning and the combining weighted proﬁle methods for four classes
target proteins: enzymes,ion channels, GPCRs and nuclear receptors.
Figure 2 - Predicted enzyme interaction network
Diamonds and circles represent drugs and target proteins, respectively. Blue and red lines indicate known
interactions and newly predicted interactions with 50 highest scores, respectively.
Figure 3 - Chemical structures
Chemical structures of drug D00477 and D00552 (from KEGG).
12Figure 4 - Predicted ion channel interaction network
Predicted ion channel interaction network. diamonds and circles represent drugs and target proteins,
respectively. Bule and red lines indicate known interactions and newly predicted interactions with 50
highest scores, respectively.
Figure 5 - Predicted GPCRs interaction network
Predicted GPCRs interaction network. diamonds and circles represent drugs and target proteins,
respectively. Blue and red lines indicate known interactions and newly predicted interactions with 50
highest scores, respectively.
Figure 6 - Predicted nuclear receptor interaction network
Predicted nuclear receptor interaction network. diamonds and circles represent drugs and target proteins,
respectively. Blue and red lines indicate known interactions and newly predicted interactions with 50
highest scores, respectively.
Figure 7 - The ROC curves of combining weighted prole
The ROC curves of combining weighted proﬁle, weighted proﬁle from chemical and genomic spaces on
GPCR data.
Figure 8 - The example of drug-protein interaction network
The example of drug-protein interaction network.
Tables
Table 1 - Statistics of the prediction performance
Table 2 - Comparison between NetLapRLS and BLM
Table 3 - Top 5 scoring predicted drug-protein interactions for the enzyme data set.
Table 4 - Top 5 scoring predicted drug-protein interactions for the ion channel data set.
Table 5 - Top 5 scoring predicted drug-protein interactions for the GPCRs data set.
Table 6 - Top 5 scoring predicted drug-protein interactions for the nuclear receptor data set.
13Table 1: Statistics of the prediction performance. The AUC is the area under the ROC curve, normalized to
100. The cutoﬀ for sensitivity and speciﬁcity is set to select the number of the interactions in the test data.
Data Methods AUC Sensitivity(%) Speciﬁcity(%)
Enzyme
Combining weighted proﬁle 92.2 6 99.9
LapRLS 95.0 53 99.9
NetLapRLS 98.3 75 99.9
Ion channel
Combining weighted proﬁle 90.7 17 99.7
LapRLS 96.1 36 99.8
NetLapRLS 98.6 72 99.9
GPCR
Combining weighted proﬁle 86.9 13 99.7
LapRLS 93.4 24 99.8
NetLapRLS 97.1 50 99.8
Nuclear receptor
Combining weighted proﬁle 81.0 11 99.4
LapRLS 85.0 16 99.4
NetLapRLS 88.8 21 99.5
Table 2: Results of BLM and NetLapRLS based on cross validation experiments 5 times. The AUC and
AUPR scores are normalized to 100. The cutoﬀ for sensitivity,speciﬁcity and PPV is set to choose the top
one percentile in the predictoin score as positive.
Data Methods AUC AUPR Sensitivity(%) Speciﬁcity(%) PPV(%)
Enzyme
BLM 96.8(0.1) 85.2(0.2) 83.2(0.2) 99.82(0.002) 82.3(0.2)
NetLapRLS 95.6(0.3) 82.6(0.6) 81.0(0.5) 99.80(0.005) 80.2(0.5)
Ion Channel
BLM 97.2(0.1) 83.2(0.4) 28.0(0.03) 99.96(0.001) 96.4(0.1)
NetLapRLS 94.7(0.3) 82.5(0.5) 28.4(0.14) 99.98(0.005) 98.1(0.5)
GPCR
BLM 94.4(0.3) 65.0(1.6) 28.0(0.8) 99.83(0.02) 83.9(2.4)
NetLapRLS 93.1(0.3) 66.0(1.5) 29.2(0.8) 99.87(0.03) 87.5(2.4)
Nuclear Receptor
BLM 84.1(0.9) 58.4(2.2) 14.0(0.6) 99.89(0.04) 90.0(3.9)
NetLapRLS 85.6(1.8) 51.6(2.3) 15.1(1.0) 99.97(0.07) 97.1(6.1)
Additional Files
None.
14Table 3: Top 5 scoring predicted drug-protein interactions for the enzyme data set.
Rank Pair Annotation
1
D00528 Anhydrous caﬀeine
hsa1549 cytochrome P450, family 2, subfamily A, polypeptide 7
2
D00542 Halothane
hsa1571 cytochrome P450, family 2, subfamily E, polypeptide 1
3
D00437 Nifedipine
hsa1559 cytochrome P450, family 2, subfamily C, polypeptide 9
4
D00410 Metyrapone
hsa1585 cytochrome P450, family 11, subfamily B, polypeptide 2
5
D00097 Salicylic acid
hsa5743 prostaglandin-endoperoxide synthase 2
Table 4: Top 5 scoring predicted drug-protein interactions for the ion channel data set.
Rank Pairs Annotation
1
D00438 Nimodipine
hsa779 calcium channel, voltage-dependent, L type, alpha 1S subunit , beta 2
2
D00477 Procainamide hydrochloride
hsa6336 sodium channel, voltage-gated, type X, alpha subunit(SCN10A)
3
D00552 Ethyl aminobenzoate
hsa6331 sodium channel, voltage-gated, type V, alpha subunit(SCN5A)
4
D02272 Quinidine sulfate
hsa3738 potassium voltage-gated channel, shaker-related subfamily, member 3
5
D00546 Desﬂurane
hsa2555 gamma-aminobutyric acid (GABA) A receptor, alpha 2(GABAR2)
Table 5: Top 5 scoring predicted drug-protein interactions for the GPCRs data set.
Rank Pair Annotation
1
D02358 Metoprolol
hsa154 adrenergic receptor, beta 2
2
D00095 Adrenaline
hsa155 beta3-adrenergic receptor agonist
3
D00371 Theophylline
hsa135 adenosine A2a receptor antagonist
4
D02354 Thiethylperazine
hsa1814 dopamine receptor D3
5
D00283 Clozapine
hsa1814 dopamine receptor D3(DRD3)
15Table 6: Top 5 scoring predicted drug-protein interactions for the nuclear receptor data set.
Rank Pair Annotation
1
D00348 Isotretinoin
hsa5915 retinoic acid receptor, beta
2
D00348 Isotretinoin
hsa5916 retinoic acid receptor, gamma
3
D00182 Norethindrone
hsa2099 estrogen receptor 1
4
D00348 Isotretinoin
hsa6256 retinoid X receptor, alpha
5
D00348 Isotretinoin
hsa6257 retinoid X receptor, beta
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